SYRA 8-K: Q3 2025 results press release furnished as Exhibit 99.1

Rhea-AI Filing Summary

Syra Health Corp. filed an 8-K announcing it furnished its third-quarter 2025 results press release. The company reported that a press release covering the quarter ended September 30, 2025 is attached as Exhibit 99.1.

The company stated the information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into other filings unless specifically referenced. The exhibit also includes forward-looking statements subject to cautionary language.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001922335 0001922335 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-41822		85-4027995
(State or other jurisdiction		(Commission		(I. R. S. Employer
of incorporation)		File Number)		Identification No.)

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of principal executive offices, including zip code)

(463) 345-8950

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.001 par value		SYRA		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Conditions.

On November 12, 2025, Syra Health Corp. issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.

Item 9.01 Financial Statements and Exhibit

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit Number		Description
99.1		Press Release dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYRA HEALTH CORP.
Date: November 12, 2025	By:	/s/ Priya Prasad
		Priya Prasad Interim Chief Executive Officer and Chief Financial Officer

FAQ

What did Syra Health (SYRA) announce in this 8-K?

The company furnished a press release with financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Which period does the Syra Health press release cover?

The press release covers the third quarter ended September 30, 2025.

Is the information in the 8-K considered 'filed' with the SEC?

No. The company states the information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.

Where can I find the detailed results for Syra Health (SYRA)?

Details are in the press release attached as Exhibit 99.1 to the 8-K.

Does the press release include forward-looking statements?

Yes. The company notes the exhibit contains forward-looking statements subject to cautionary language.

What is Syra Health’s trading symbol and market?

Syra Health’s Class A Common Stock trades under SYRA on the OTCQB.